Single Arm Phase II Study to Assess the Efficacy of Pembrolizumab Plus Radiotherapy or Ablation in Metastatic Colorectal Cancer Patients
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 10 Apr 2018
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- 04 Apr 2018 Planned End Date changed from 1 Apr 2018 to 1 Apr 2019.
- 04 Apr 2018 Planned primary completion date changed from 1 Apr 2018 to 1 Apr 2019.
- 05 Dec 2017 Status changed from recruiting to active, no longer recruiting.